ClinicalTrials.gg
Enrolling by invitationNCT06564467Updated Aug 22, 2024

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202

A Phase 1 interventional study of JMT202 and Placrbo in Healthy Subjects, sponsored by Shanghai JMT-Bio Inc.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JMT202 in Healthy Participants.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Shanghai JMT-Bio Inc. is the lead sponsor of 43 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 18 - 60 years (inclusive), male or female;
  2. : 18.0-26.0 kg/m\^2 (inclusive), with a minimum weight of 50.0 kg (inclusive) for male and 45.0 kg (inclusive) for female;
  3. Normal vital signs; Normal physical examination; Normal findings; Normal laboratory examination; Normal imaging examination (X-ray);
  4. Participants and their partners agree to use effective and reliable methods to avoid pregnancy, and male subjects had no plans to donate sperm, and female subjects had no plans to donate eggs, from the time they signed the to 6 months after the end of the study;
  5. Participants must give informed consent before the trial, fully understand the content, procedures and possible adverse reactions, and voluntarily sign a written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution or known history of allergy to the components of the study drug or similar drugs;
  2. Participants with a history of serious diseases, including pancreas, cardiovascular, liver, kidney, blood and lymphatic, central nervous system, and gastrointestinal systems, or other important diseases that may affect the absorption, metabolism, or excretion of the study drug;
  3. Participants with a history of cancer, mental illness, depression, anxiety, and epilepsy;
  4. With diabetes, thyroid dysfunction or have other affect blood glucose metabolic endocrine disease;
  5. >6.5% at screening;
  6. or ALT>1.5 times the at screening;
  7. Fasting triglycerides>1.7 mmol/L at screening;
  8. The estimated (eGFR) during screening was \< 90 mL/min/1.73 m\^2 (calculated by simplified MDRD formula);
  9. Screening, vital signs has one or more check exception: temperature \< 35.5 ℃ or > 37.2 ℃, pulse \< 60 times/min or > 100 times/min, systolic blood pressure ≥ 140 mmHg or \< 90 mmHg, diastolic blood pressure ≥ 90 mmHg or \< 60 mmHg;
  10. During screening, participants with prolonged /QTc interval (QTcF > 450 ms in male, > 470 ms in female);
  11. Participants with non-negative test for any of , antibodies, syphilis antibodies, and antibodies;
  12. Blood loss or blood donation of more than 400 mL within 3 months prior to administration;
  13. Those who underwent major surgery within 6 months prior to initial administration;
  14. Vaccination was administered within 28 days before the trial or within 1 week after the planned dose;
  15. Antibody drugs targeting β-Klotho/FGFR1c have been used before screening;
  16. Use of any drug for therapeutic purposes within 2 weeks prior to administration or within the 5 half-lives of the drug (whichever is longer), including prescription drugs, over-the-counter drugs or health care products, Chinese herbs;
  17. Participated in another study within 3 months before administration; Or plans to participate in another drug trial during the study
  18. Those who have any special diet requirements, cannot accept unified diet and schedule;
  19. Those who smoked more than 5 cigarettes per day within 3 months prior to screening and/or did not agree to refrain from using any tobacco products during the study;
  20. Regular drinkers within 3 months prior to screening, female more than 14 g (i.e.,145 mL wine, 497 mL beer or 44 mL low-alcohol liquor), male more than 28 g (i.e.,290 mL wine, 994 mL beer or 88 mL low-alcohol liquor), or within 48 h before administration taking any alcohol, and/or test positive for breath alcohol;
  21. Regular drinkers within 1 months prior to screening, i.e., those who consume excessive amounts of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) per day, and/or do not agree that tea, coffee and/or caffeinated foods, grapefruit and/or grapefruit juice, and/or products containing opium poppy are prohibited during the study;
  22. A history of drug abuse, and/or drug use within 3 months prior to screening, and/or positive urine drug screening;
  23. There were symptoms such as dermatitis or skin abnormalities in and around the site of administration;
  24. Participants who were dizzy with needles, dizzy with blood, unable to tolerate blood collection by venipuncture, or with poor peripheral venous access conditions;
  25. Pregnant or lactating women; blood HCG positive, and/or women of childbearing age who have unprotected sex with their partner within 30 days before screening;
  26. The researchers think doesn't fit to participate in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    JMT202 SAD experimental group

    Participants in SAD experimental groups will receive a single subcutaneous injection of JMT202 on Day 1.

    Drug: JMT202

  • Placebo comparator
    Placebo SAD group

    Participants in SAD experimental groups will receive a single subcutaneous injection of placebo on Day 1.

    Drug: Placrbo

Interventions

  • DrugJMT202

    subcutaneous injection

  • DrugPlacrbo

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. The Number of adverse events (AEs) electrocardiograms

    To investigate the safety and tolerability by assesment of AEs following administration.

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  2. Number of participants with clinically significant change from baseline in vital signs

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  3. Number of participants with clinically significant change from baseline in electrocardiogram (ECG) findings

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  4. Number of participants with clinically significant abnormalities in physical examination

    Time frame: Pre-dose and multiple timepoints no less than 50 days

Secondary outcomes

  1. Area under the concentration-time curve from 0 to the collection time t (AUC0-t)

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  2. Area under the concentration-time curve from 0 to infinity (AUC0-∞)

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  3. Time to maximum concentration (Tmax)

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  4. Serum Maximum concentration (Cmax)

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  5. Half-Life (t1/2)

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  6. Anti-drug antibody (ADA) prevalence in blood before study treatment and at the Follow-up Visit

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  7. Absolute change in High molecular weight adiponectin

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  8. Absolute change in weight

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  9. Absolute change in glycosylated hemoglobin

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  10. Absolute change in fasting insulin level

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  11. Absolute change in fasting glucose

    Time frame: Pre-dose and multiple timepoints no less than 50 days

  12. Absolute change in blood lipoprotein

    Time frame: Pre-dose and multiple timepoints no less than 50 days

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jan 2025, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Aug 21, 2024
StartActual
Jul 23, 2024
Primary completionEst.
Jan 10, 2025
CompletionEst.
Jul 10, 2025
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06564467
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Jul 23, 2024
Primary completion
Jan 10, 2025 (estimated)
Completion
Jul 10, 2025 (estimated)
Last update
Aug 22, 2024

Study contacts

Jianping Li, doctor
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion